HER3-DXd; an antibody-drug conjugate composed of patritumab, a fully human anti-HER3 (ERBB3) IgG1 monoclonal antibody, linked via a cleavable tetrapeptide to deruxtecan (DXd), a membrane-permeable exatecan-derived topoisomerase I inhibitor. It binds HER3 on tumor cells, is internalized, and releases DXd in lysosomes to induce DNA single-strand breaks and apoptosis, with a bystander effect.
Fully human anti-HER3 (ERBB3) IgG1 antibody linked via a cleavable tetrapeptide to the topoisomerase I inhibitor DXd. Binds HER3 on tumor cells, is internalized, and releases DXd in lysosomes to inhibit topo I, causing DNA single-strand breaks and apoptosis, with a membrane-permeable bystander killing effect.
NO
INDIRECT
The ADC binds HER3 on tumor cells and is internalized; the cleaved DXd payload inhibits topoisomerase I inside the cell, causing DNA damage and apoptosis. Topoisomerase I is the payload’s enzymatic target, not the antigen used for targeting.
Polyclonal antibody preparation that depletes T lymphocytes for induction immunosuppression.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated ADCC, with additional T-cell apoptosis and functional inhibition, producing potent immunosuppression.
YES
DIRECT
ATG contains antibodies that bind CD25 on T cells, triggering complement-dependent cytotoxicity and Fc-mediated ADCC, with additional apoptosis, leading to depletion of CD25+ cells.
Humanized anti-EGFR IgG1 monoclonal antibody that blocks EGFR ligand binding/activation, suppresses MAPK/ERK and PI3K/AKT signaling, and mediates ADCC.
Humanized IgG1 monoclonal antibody targeting EGFR; binds the extracellular domain to block ligand binding and receptor activation, suppressing MAPK/ERK and PI3K/AKT signaling, inhibiting proliferation and survival of EGFR-overexpressing tumor cells, and engaging Fc-mediated ADCC.
YES
DIRECT
Anti-EGFR IgG1 binds EGFR and its Fc engages FcγR+ immune effectors to mediate ADCC (NK/macrophage killing); may also trigger CDC. EGFR signaling blockade is cytostatic.
Bispecific antibody-drug conjugate targeting EGFR and HER3; after internalization, releases a topoisomerase I inhibitor payload (brengitecan) to induce DNA damage and tumor cell death.
Bispecific ADC that binds EGFR and HER3 on tumor cells, is internalized, and releases the topoisomerase I inhibitor payload brengitecan to induce DNA damage and tumor cell death.
YES
DIRECT
The bispecific ADC binds EGFR on tumor cells, is internalized, and releases the topoisomerase I inhibitor brengitecan, causing DNA damage and cell death.
Bispecific antibody-drug conjugate targeting EGFR and HER3; after internalization, releases a topoisomerase I inhibitor payload (brengitecan) to induce DNA damage and tumor cell death.
Bispecific ADC that binds EGFR and HER3 on tumor cells, is internalized, and releases the topoisomerase I inhibitor payload brengitecan to induce DNA damage and tumor cell death.
YES
DIRECT
The ADC binds HER3 (and EGFR) on tumor cells, is internalized, and releases the topoisomerase I inhibitor brengitecan, causing DNA damage and tumor cell death.